新型冠状病毒肺炎中的凝血功能障碍
Coagulopathy in COVID-19.
作者信息
Lio Ka U, Rali Parth
机构信息
Medical student, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Division of Thoracic Medicine and Surgery, Temple University Hospital, Philadelphia, Pennsylvania, USA.
出版信息
Lung India. 2021 Mar;38(Supplement):S53-S57. doi: 10.4103/lungindia.lungindia_226_20.
Hemostatic derangement is a hallmark in severe COVID-19. Markedly elevation of D-dimer and fibrinogen degradation product levels were observed in patients with severe COVID-19 higher and 71.4% of nonsurvivors met the International Society of Thrombosis and Haemostasis criteria of disseminated intravascular coagulation (DIC). Although the clinical and epidemiological features of COVID-19 have been well-described, the underlying mechanism influencing disease severity remains to be elucidated. Herein, the aim of this review article is to evaluate hemostasis in the pathogenesis of COVID-19 and its role in the management of this unprecedented pandemic.
凝血功能紊乱是重症新型冠状病毒肺炎（COVID-19）的一个标志。在重症COVID-19患者中观察到D-二聚体和纤维蛋白原降解产物水平显著升高，且71.4%的非幸存者符合国际血栓与止血学会弥散性血管内凝血（DIC）的标准。尽管COVID-19的临床和流行病学特征已得到充分描述，但其影响疾病严重程度的潜在机制仍有待阐明。在此，这篇综述文章的目的是评估凝血功能在COVID-19发病机制中的作用及其在应对这一前所未有的大流行中的作用。
Zotero 插件